Our EQA scheme timetable was impacted by the COVID-19 pandemic. Please click the link below for the revised timetable (published 01.07.2020).
Please visit the READ MORE link below to learn more about this initiative.
Manchester, UK, 6th March 2020: EMQN CIC today announced it is collaborating with GenQA to launch a pilot EQA scheme for HRR gene testing in patients with advanced Prostate Cancer.
Manchester, UK, 26th February 2020: EMQN CIC today announced it is collaborating with GenQA to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
Membership of EMQN gives your laboratory access to world class resources in genomics to help improve your performance.
Is your laboratory undertaking genomic testing of HRR gene(s) for prostate cancer? If you are, then you may be in… https://t.co/9CC5mvWRHQ
Is your laboratory undertaking genomic testing of HRR gene(s) in prostate cancer? If you are, then you may be inter… https://t.co/yh94A8JoO1
Round 2 of the Coronavirus Outbreak Preparedness EQA Pilot is now open for registration. login to your EMQN account… https://t.co/m9LgXTidmt
The FINAL results from 2020 germline EQA schemes were published TODAY. User are recommended to log in to their EMQN… https://t.co/l0hzfZyIBl
Recording of 2019 BRCA ovarian EQA scheme webinar now available via the EMQN website. Click here… https://t.co/1ReKUPCGMZ